<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Endocrinol Metab</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Endocrinol Metab</journal-id><journal-id journal-id-type="publisher-id">IJEM</journal-id><journal-title-group><journal-title>Indian Journal of Endocrinology and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">2230-8210</issn><issn pub-type="epub">2230-9500</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22701844</article-id><article-id pub-id-type="pmc">3354942</article-id><article-id pub-id-type="publisher-id">IJEM-16-47</article-id><article-id pub-id-type="doi">10.4103/2230-8210.94259</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Pleiotropic effects of incretins</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gupta</surname><given-names>Vishal</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><italic>Department of Endocrinology, Jaslok Hospital and Research Centre, Mumbai, India</italic></aff><author-notes><corresp id="cor1"><bold>Corresponding Author:</bold> Dr. Vishal Gupta, Department of Endocrinology, Jaslok Hospital and Research Centre, 15, Dr. Deshmukh Marg, Pedder Road, Mumbai, India. E-mail: <email xlink:href="enquiry@drvishalgupta.com">enquiry@drvishalgupta.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2012</year></pub-date><volume>16</volume><issue>Suppl1</issue><fpage>S47</fpage><lpage>S56</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Endocrinology and Metabolism</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Drugs that augment the incretin system [glucagon like peptide (GLP) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] represent a novel class of anti-hyperglycemic agents that have shown to improve the health and survival of beta-cells (improvement in postprandial hyperglycemia) and suppress glucagon (improvement in fasting hyperglycemia). The incretins represent a large family of molecules referred to as the &#x0201c;glucagon superfamily of peptide hormones&#x0201d; of which more than 90% of the physiological effects of incretins are accomplished by GLP-1<sub>7-37</sub> and GLP1<sub>7-36</sub> amide and gastric insulinotropic peptide (GIP). GLP-1 mediates its effects via the GLP-1 receptor, which has a wide tissue distribution [pancreas, lung, heart, vascular smooth muscle cells, endothelial cells, macrophages and monocytes, kidney, gastrointestinal tract (stomach and intestine), central nervous system (neoortex, cerebellum, hypothalamus, hippocampus, brainstem nucleus tractus solitarius) and peripheral nervous system]. This would imply that the incretin system has effects outside the pancreas. Over time data has accumulated to suggest that therapies that augment the incretin system has beneficial pleiotrophic effects. The incretins have shown to possess a cardiac-friendly profile, preserve neuronal cells and safeguard from neuronal degeneration, improve hepatic inflammation and hepatosteatosis, improve insulin resistance, promote weight loss and induce satiety. There is growing evidence that they may also be renoprotective promoting wound healing and bone health.</p></abstract><kwd-group><kwd>Extrapancreatic</kwd><kwd>gliptins</kwd><kwd>glucagon like peptide analogues</kwd><kwd>glucagon like peptide</kwd><kwd>incretin mimetics</kwd><kwd>incretins</kwd><kwd>pleiotrophic</kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>I<sc>NTRODUCTION</sc></title><p>More than 50% of patients with type 2 diabetes mellitus (T2DM) have a glycosylated hemoglobin (HbA1c) level of &#x0003e;7% and are inadequately controlled.[<xref ref-type="bibr" rid="ref1">1</xref>] Drugs such as metformin and sulfonylurea (SU) have traditionally been the mainstay of therapy despite the knowledge that the combination may be cardiac unfriendly (UKPDS) and may result in a progressive decline in (beta)-cell function, and by 3 years, up to 50% of diabetic patients can require an additional pharmacological agent to maintain the HbA1c to &#x0003c;7.0% (UKPDS).[<xref ref-type="bibr" rid="ref2">2</xref>&#x02013;<xref ref-type="bibr" rid="ref4">4</xref>] Moreover, these drugs do not address the pathogenesis of T2DM, except metformin that helps improve insulin resistance (hepatic more than peripheral).</p><p>Drugs that augment the incretin system [glucagon like peptide (GLP) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] represent a novel class of anti-hyperglycemic agents that have shown to improve the health and survival of beta-cells (improvement in postprandial hyperglycemia), suppress glucagon (improvement in fasting hyperglycemia), improve insulin resistance (modest effect) and influence energy intake (augment satiety signal) with minimal, if at all, any side effects (weight neutral and non-hypoglycemic). The incretins address most of the proposed pathogenetic mechanisms involved in the development of T2DM.[<xref ref-type="bibr" rid="ref2">2</xref>]</p><p>Over time, these agents have shown to have a cardiac-friendly profile, preserve neuronal cells and safeguard from neuronal degeneration, improve hepatic inflammation and hepatosteatosis, improve insulin resistance, promote weight loss and induce satiety.[<xref ref-type="bibr" rid="ref5">5</xref>] There is growing evidence that they may also be renoprotective and help with wound healing.</p></sec><sec id="sec1-2"><title>G<sc>UT</sc> P<sc>EPTIDES</sc>/I<sc>NCRETINS</sc></title><p>In 1902, Bayliss and Starling identified the first gut hormone called &#x0201c;secretin&#x0201d; and suggested that it may be involved in glucose homeostasis. In 1930, crude secretin was successfully divided into two fractions by a Belgian physiologist named Jean La Barre. One fraction was shown to stimulate exocrine pancreatic secretion (secretin) and the other was shown to lower plasma glucose (incretin). In 1932, La Barre coined the term &#x0201c;incr&#x000e9;tine.&#x0201d;[<xref ref-type="bibr" rid="ref6">6</xref>&#x02013;<xref ref-type="bibr" rid="ref8">8</xref>]</p><p>Incretins, namely, GLP-1 and gastric insulotropic peptide (GIP), have shown to dispose glucose far more efficiently following an oral mixed meal (incretin effect).[<xref ref-type="bibr" rid="ref9">9</xref>] They represent a large family of molecules referred to as the &#x0201c;glucagon superfamily of peptide hormones.&#x0201d; More than 90% of the physiological effects of incretins are accomplished by GLP1<sub>7-37</sub> and GLP1<sub>7-36</sub> amide and GIP.</p><p>GLP-1 circulates as two equipotent forms, GLP1<sub>7-37</sub> and GLP1<sub>7-36</sub> amide, and is secreted by neuroendocrine L-cells present in the distal small intestine in response to a carbohydrate/fat meal. GLP1<sub>7-36</sub> constitutes 80% of circulating GLP-1. It is rapidly cleared by the kidney and degraded by DPP-4 (a type II membrane peptidase resembling CD26) even before it leaves the gastrointestinal tract. DPP-4 was discovered in 1996. The half-life of circulating native bioactive GLP-1 is less than 2 minutes. Gliptins work by inhibiting DPP-4 and raising the concentration of circulating GLP-1 as many as twofold to threefold. Incretin mimetics (exanatide, liraglutide) work by stimulating the GLP-1 receptor (GLP-1R) directly. GIP is secreted by neuroendocrine K-cells present in stomach and proximal small intestine and has a half-life of approximately 7 minutes in healthy individuals and 5 minutes in patients with T2DM, being degraded by DPP-4 also. GIP is rapidly cleared through the kidney.[<xref ref-type="bibr" rid="ref9">9</xref>&#x02013;<xref ref-type="bibr" rid="ref17">17</xref>]</p><p>GLP-1 has a wide tissue distribution and acts via the GLP-1R that belongs to the class B family of 7-transmembrane&#x02013;spanning, heterotrimeric G-protein&#x02013;coupled receptors functionally associated with adenylate cyclase. It has been identified in pancreas, lung, heart, vascular smooth muscle cells, endothelial cells, macrophages and monocytes, kidney, gastrointestinal tract (stomach and intestine), central nervous system (brain) and peripheral nervous system. The brain and cardiac tissue express the same GLP-1R as is expressed on pancreatic tissue, in contrast to peripheral human tissue (skeletal muscle, adipose tissue, liver) where the receptors bear some degree of homology to pancreatic GLP-1R.[<xref ref-type="bibr" rid="ref12">12</xref>&#x02013;<xref ref-type="bibr" rid="ref16">16</xref>] In the brain, the GLP-1R is found only on neurons and not on glial cells. It is present on mainly large output neurons such as pyramidal neurons, dentate granule neurons and Purkinje cells. GLP-1Rs are found on dendrites in and around synapses, suggesting that they directly modulate synaptic activity and plasticity. In the brainstem, GLP-1R is mostly distributed in the brainstem nucleus (caudal part of nucleus tractus solitarius). Hypothalamus [dorsomedial (DMN), paraventricular (PVN), ventromedial (VMN), lateral and arcuate (ARC) and supraoptic nuclei], sensory circumventricular organs such as the subfornical organ, organum vascularum, laminae terminus, and the area postrema express GLP-1R in high density. Other areas that express GLP are neocortex, cerebellum and hippocampus. Although it is believed that the liver (hepatocyte) possesses the GLP-1R, it is clearly different compared to the native GLP-1R. Simulation of the liver GLP-1R results in anabolic effect, an action opposite to that seen with glucagon (neoglucogenesis and glycogenolysis). It is thus believed that although GLP-1R truly exists on hepatocytes, it must be different from the known GLP-1R, produced either by an unidentified gene locus encoding a second GLP-1R, or it may be an alternatively spliced receptor related to the superfamily of glucagon-related peptide receptors.[<xref ref-type="bibr" rid="ref18">18</xref>&#x02013;<xref ref-type="bibr" rid="ref20">20</xref>]</p></sec><sec id="sec1-3"><title>C<sc>URRENTLY</sc> A<sc>VAILABLE</sc> G<sc>LIPTINS AND</sc> I<sc>NCRETIN</sc> M<sc>IMETICS</sc></title><sec id="sec2-1"><title>Gliptins</title><p>
<list list-type="bullet"><list-item><p>Sitagliptin (Merck Sharp and Dohme Corp., approved as Januvia by US FDA in 2006)</p></list-item><list-item><p>Vidagliptin (Novartis, approved as Galvus by EU in 2007)</p></list-item><list-item><p>Saxagliptin (Bristol-Myers Squibb, approved as Onglyza by US FDA in 2010)</p></list-item><list-item><p>Linagliptin (Boerhinger Ingelheim, approved as Tradjenta by US FDA in 2011)</p></list-item><list-item><p>Alogliptin (developed by Takeda Pharmaceutical Company Limited, approved for use in Japan)</p></list-item><list-item><p>Dutogliptin (being developed by Phenomix Corporation)</p></list-item><list-item><p>Gemiglaptin (being developed by LG Life Sciences)</p></list-item><list-item><p>(Sitagliptin, Vidagliptin, Saxagliptin are approved for use in India)</p></list-item></list>
</p></sec><sec id="sec2-2"><title>Incretin mimetics</title><p>
<list list-type="bullet"><list-item><p>Exanatide (EliLilly, approved as Exanatide by US FDA in 2005)</p></list-item><list-item><p>Liraglutide (Novonordisk, approved as Victoza by US FDA in 2010)</p></list-item><list-item><p>(Exanatide, Liraglutide are approved for use in India)</p></list-item></list>
</p></sec></sec><sec id="sec1-4"><title>C<sc>URRENT</sc> P<sc>OSITION OF</sc> D<sc>RUGS THAT</sc> W<sc>ORK ON THE</sc> I<sc>NCRETIN</sc> A<sc>XIS IN THE</sc> M<sc>ANAGEMENT OF</sc> T2DM</title><p>Amongst all currently available anti-diabetic agents, gliptins address most of the &#x0201c;pathogenetic octet&#x0201d; components of T2DM, as proposed by Ralf Dfranzo. They have found themselves occupying a unique position in the management of T2DM based on the fact that they are weight neutral (gliptins) or weight reducing (incretin mimetics) and virtually free of hypoglycemia. For this very reason, they are commonly advised as second-line therapy along with an insulin sensitizer. They are indicated and approved for use as follows:</p><p>
<list list-type="order"><list-item><p>First line in patients with HbA1c &#x0003c;7%</p></list-item><list-item><p>Second line as add-on therapy to pre-existing monotherapy (metfromin, SU, TZD, alpha-glucosidase inhibitor, miglitinide) for uncontrolled T2DM with HbA1c &#x0003e;7%. Caution is advised along with the use of SU, as it may potentiate its action and cause hypoglycemia. Dose titration of SU (reduce to half existing dose) is recommended when used along with gliptin or GLP-1 analogue.</p></list-item><list-item><p>Third line as add-on therapy to pre-existing dual combination therapy (metfromin, SU, TZD, alpha-glucosidase inhibitor, miglitinide).</p></list-item></list>
</p><p>NICE UK, recognizes the enormous potential of the drugs (weight neutral and virtually free of hypoglycemia) and states that the drugs should be continued as long as they can maintain an HbA1c reduction of greater than 0.5% over a 6-month period. This might change in the future assuming the profound non-glycemic benefits that they have shown to possess.[<xref ref-type="bibr" rid="ref21">21</xref>&#x02013;<xref ref-type="bibr" rid="ref23">23</xref>]</p></sec><sec id="sec1-5"><title>P<sc>LEIOTROPIC</sc> E<sc>FFECTS</sc></title><sec id="sec2-3"><title>Cytoprotection</title><p>GLP-1R stimulation has been associated with cytoprotection and anti-apoptosis in all tissue types bearing the receptor. The trophic actions are probably mediated via protein kinase A (PKA) and phosphoinositide 3-kinase (PI3K) signaling. GLP-1R stimulation has been associated with suppression of pro-apoptotic protein, Bax, and stimulation of anti-apoptotic protein, Bcl-2; thereby favorably modifying the Bax/Bcl-2 ratio, supporting cell survival. Pancreas, brain and heart have been shown to express exactly the same GLP-1R type and it would only be appropriate to suggest that the cytoprotective benefit would in least extend to these tissue types as they bear the same receptor type.[<xref ref-type="bibr" rid="ref24">24</xref>&#x02013;<xref ref-type="bibr" rid="ref26">26</xref>]</p></sec></sec><sec id="sec1-6"><title>C<sc>ARDIOVASCULAR</sc> E<sc>FFECTS</sc></title><p>Both intact GLP-1<sub>7-36</sub> amide and GLP-1<sub>9-36</sub> amide have demonstrated <italic>GLP-dependent</italic> cardioprotective effects in preclinical studies. Studies have also demonstrated cardioprotective effects following use of GLP-1R agonists in GLP-1R knockout mice [Glp1r(&#x02013;/&#x02013;)] suggesting <italic>GLP-1 independent</italic> effects. Furthermore, mice lacking the GLP-1R were reported to have lower heart rates, worse left ventricular (LV) diastolic function, greater LV wall thickening, and impaired LV contractile function.[<xref ref-type="bibr" rid="ref27">27</xref>&#x02013;<xref ref-type="bibr" rid="ref29">29</xref>]</p><p>The proposed mechanisms to explain the cardiac benefits are as follows:</p><p>
<list list-type="order"><list-item><p>The human heart usually uses fats as metabolic fuel in the normoxic state. When acutely stressed (ischemic), it switches from lipid metabolism to carbohydrate oxidation, which is although adaptive initially, eventually leads to insulin resistance and a loss of metabolic flexibility, which is detrimental to the heart. GLP-1R stimulation helps improve insulin sensitivity and shifts cardiac metabolism in favor of cardioprotection.[<xref ref-type="bibr" rid="ref30">30</xref>&#x02013;<xref ref-type="bibr" rid="ref32">32</xref>]</p></list-item><list-item><p>Pre-clinical studies have shown that GLP-1 up-regulates the expression of glucose transport protein (GLUT)-2 and -4, which in turn improves insulin resistance. GLUTs represent a family of proteins that help facilitate the transport of glucose across the plasma membrane. In the myocyte, GLUT-4 is found predominantly distributed between sarcolemmal and T tubule membranes. GLUT-4 expression is markedly reduced in T2DM. GLP-mediated GLUT-4 translocates to the myocyte surface to increase glucose uptake. GLUT-2 is the most abundant isoform in liver and pancreatic B-cells, which when up-regulated improves peripheral glucose uptake.[<xref ref-type="bibr" rid="ref33">33</xref><xref ref-type="bibr" rid="ref34">34</xref>]</p></list-item><list-item><p>GLP-1 has shown to decrease pyruvate and lactate concentrations both in normoxic and ischemic conditions of the heart, suggesting cardioprotective effects.[<xref ref-type="bibr" rid="ref35">35</xref>]</p></list-item><list-item><p>Anti-apoptosis of cardiac myocyte - GLP-1 seems also to reduce infarct size in rats, when given either prior to ischemia (as a preconditioning mimetic) or directly at reperfusion. Other potential cardioprotective markers enhanced by GLP-1 agonists are Bcl-2 family proteins (anti-apoptosis) and heme oxygenase-1 (antioxidant gene, shown to reduce LV fibrosis and remodeling and improve LV function post myocardial infarction).[<xref ref-type="bibr" rid="ref36">36</xref>&#x02013;<xref ref-type="bibr" rid="ref39">39</xref>]</p></list-item></list>
</p><sec id="sec2-4"><title>Potential benefits</title><p>
<list list-type="order"><list-item><p><bold>Ionotropic</bold>: GLP-1 agonists have shown to limit infarct size and improve LV function. In a study that assessed LV function following a myocardial infarction, a significant improvement in ejection fraction (from 29 &#x000b1; 2% to 39 &#x000b1; 2%) and regional functional recovery in the peri-infarct zone was observed, which were independent of changes in blood pressure or heart rate, suggesting cardioprotection.[<xref ref-type="bibr" rid="ref40">40</xref><xref ref-type="bibr" rid="ref41">41</xref>]</p></list-item><list-item><p><bold>Blood pressure</bold>: In humans, the use of GLP-1 analogues (exenatide and liraglutide) and gliptins (sitagliptin) has shown a significant reduction in both systolic and diastolic blood pressure when compared with placebo. The main mechanism for this antihypertensive effect, however, seems to be related to weight loss. In addition, GLP therapy has shown to have a natriuretic/diuretic effect (inhibiting sodium reabsorption in the proximal tubule and angiotensin II), peripheral vasodilatory effect and endothelial function stabilizing effect in preclinical studies, all shown to contribute to improvements in blood pressure.[<xref ref-type="bibr" rid="ref42">42</xref>&#x02013;<xref ref-type="bibr" rid="ref48">48</xref>]</p></list-item><list-item><p><bold>Vascular endothelium</bold>: GLP-1R agonists have shown to inhibit monocyte/macrophage accumulation in the arterial wall, inhibit expression of inflammatory marker [tumor necrosis factor-alpha (TNF-alpha)], inhibit hyperglycemic-mediated induction of expression of plasminogen activator inhibitor type-1 (pro-coagulant), adhesion molecules [vascular cell adhesion molecule-1 (VCAM-1)] and promote vascular relaxants (nitric oxide). The same results have been replicated by gliptins (sitagliptin) that have shown to improve inflammatory cytokines [monocyte chemoattractant protein (MCP)-1, interleukin (IL)-6, IL-12, IL-12] at the level of adipose tissue (improved insulin resistance) and systemically. The net result seems to be amelioration of endothelial function and stabilization of fatty plaques, which should eventually translate into direct protective effects of GLP-1 on the progression of atherosclerosis.[<xref ref-type="bibr" rid="ref49">49</xref>&#x02013;<xref ref-type="bibr" rid="ref54">54</xref>]</p></list-item><list-item><p><bold>Dyslipidemia</bold>: GLP-1 agonists have been shown to increase high-density lipoprotein (HDL) and reduce triglyceride, apolipoprotein B48 (apoB48, a component of chylomicrons, rich in triacylglycerol, produced after fat ingestion). Most of these effects, however, have been shown to be related to weight loss rather than the direct effect of the drugs. Improvements in postprandial lipemia are seen with both DPP-4 inhibitors and GLP-1 agonists. However, the mechanism seems unclear. Postprandial lipemia has been shown to be atherogenic. It may, therefore, be extrapolated that use of GLP-1 agonists may have an anti-atherosclerotic effect.[<xref ref-type="bibr" rid="ref55">55</xref>&#x02013;<xref ref-type="bibr" rid="ref57">57</xref>]</p></list-item><list-item><p><bold>Weight loss</bold>: As little as a 5% reduction in weight can improve glycemic control, blood pressure and lipid levels. In a prospective study, the effect of intentional weight loss on mortality in overweight individuals with diabetes was studied. It was seen that a weight loss of 34% was associated with a 25% reduction in total mortality and a 28% reduction in cardiovascular disease (CVD) and diabetes mortality. An intentional weight loss of 20&#x02013;29 lb was associated with the largest reduction in mortality (~33%). GLP-1 agonists have been associated with an average weight loss of approximately 1&#x02013;10 kg over a 1-year period in studies carried out in both controlled and real life setting. A retrospective analysis of patients treated with GLP-1R agonists showed that weight reduction was associated with a favorable cardiovascular risk profile.[<xref ref-type="bibr" rid="ref58">58</xref>&#x02013;<xref ref-type="bibr" rid="ref63">63</xref>]</p></list-item></list>
</p></sec></sec><sec id="sec1-7"><title>E<sc>FFECTS ON THE</sc> N<sc>ERVOUS</sc> S<sc>YSTEM</sc></title><p>Patients with T2DM are predisposed to the development of neurodegenerative disorders like Alzheimer's disease and the association has been referred to as <italic>type 3 diabetes mellitus</italic>. Desensitization of insulin receptors has been observed in the brains of patients with Alzheimer's disease, and any process (GLP-1 analogues or DPP-4 inhibitors) that can up-regulate the insulin receptors should theoretically have the potential to improve the clinical course.[<xref ref-type="bibr" rid="ref64">64</xref>&#x02013;<xref ref-type="bibr" rid="ref67">67</xref>] Augmentation of the incretin system has demonstrated the potential advantage of preservation of neuronal cells. GLP-1 may gain access to the brain via either local production of GLP-1 within the brain or uptake of intestinally derived GLP-1 in the circulation. There is some skepticism with regard to GLP-1's central actions derived from the gastrointestinal tract as it has a very short circulating life, being rapidly inactivated by DPP-4. GLP-1 inhibits eating responses (taste aversion, satiety) via its action on GLP-1R.</p><p>The proposed mechanisms to explain these benefits include the following:</p><p>
<list list-type="order"><list-item><p><bold><italic>Modulation of peripheral taste sensation</italic></bold>: GLP analogues can directly influence the taste receptors. Human GLP-1 is found in mammalian taste cells (type 2 and type 3). The weight loss observed with GLP receptor agonists has been associated with reduction in food intake and weight loss in rats. GLP-1 may help modulate taste sensation which may further contribute to its anorexigenic effect.[<xref ref-type="bibr" rid="ref68">68</xref>]</p></list-item><list-item><p><bold><italic>Central modulation of energy intake</italic></bold>: Preclinical studies indicate enhanced expression of c-Fos in the nucleus tractus solitarii, area postrema and central nucleus of the amygdale in response to GLP, which are central regulators of energy metabolism. Specific hypothalamic nuclei (DMN, PVN, ARC and VMN) serve as control centers for appetite. The ARC nucleus lies outside the blood&#x02013;brain barrier and is the major target for peripheral hormones that regulate appetite, like GLP. The ARC contains two distinct types of neurons, anorexigenic [neuropeptides pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART)] and orexigenic [neuropeptide Y (NPY) and agouti-related protein (AgRP)]. There exist several NPY-receptors (NPY-R); NPYR1- and Y5-receptor activation appears to stimulate appetite, while NPYRY2- and Y4-receptor activation suppresses food intake via presynaptic inhibition of NPY release. GLP-1 has shown to antagonize the orexigenic effects of NPY. Central GLP-1 augmentation results in an anorexigenic effect with a reduction in appetite by 12% approximately for the subsequent meal.[<xref ref-type="bibr" rid="ref69">69</xref>&#x02013;<xref ref-type="bibr" rid="ref74">74</xref>] Also, corticotropin-releasing hormone and thyrotropin-releasing hormone are anorexigenic peptides expressed in the PVN nuclei of hypothalamus. GLP-1 has shown to increase the release of corticotropin in the hypothalamus, further contributing to appetite suppression.[<xref ref-type="bibr" rid="ref75">75</xref>]</p></list-item><list-item><p><bold><italic>Peripheral modulation of energy intake in concert with central mechanisms</italic></bold>: In response to food and nutrients in the proximal gastrointestinal tract, signals are carried from the lamina propria via the vagal afferents (parasympathetic system) to the center. The nucleus tractus solitarius primarily receives afferents from the vagus. Studies have shown that the caudal neurons of the nucleus of the solitary tract containing GLP-1 project to the PVN nucleus of the hypothalamus (satiety center) to cause central suppression of appetite and food intake, participating in the regulation of energy intake. Efferents from the center are also generated to project back to the gastrointestinal tract, resulting in gastric slowing by a mechanism called &#x0201c;ileal-break.&#x0201d; Preclinical studies have also shown that the production of GLP-1 is dependent on the presence of an intact autonomic nervous system, without which weight gain results. It is tempting to speculate that this may constitute a prandial satiety signal. <italic>Leptin</italic> is a quantitative marker and product of the <italic>ob</italic> gene in white adipose tissue. The leptin receptor has been found on the membrane of the GLP-1 secreting intestinal L-cells. Leptin can stimulate GLP-1 secretion from fetal rat and human intestinal L-cells in a dose-dependent manner. Leptin has been shown to activate the hypothalamic circuits, leading to the inhibition of food intake. T2DM and obesity is associated with leptin receptor resistance leading to reduced GLP-1 secretion and hypothalamic activation in favor of increased energy intake.[<xref ref-type="bibr" rid="ref76">76</xref>&#x02013;<xref ref-type="bibr" rid="ref78">78</xref>]</p></list-item></list>
</p><p>The incretins have numerous pleitropic effects with clear benefits to the neuronal system. Central augmentation of the incretin system has been shown to protect neuronal cells (neuroprotection), influence neurobehavioral changes (enhanced learning, cognition, spatial orientation) and regulate food and energy intake (weight loss). This adds a new dimension to the use of GLP-1 augmenting therapies for patients with diabetes.</p></sec><sec id="sec1-8"><title>G<sc>ASTROINTESTINAL AND</sc> H<sc>EPATOBILIARY</sc> E<sc>FFECTS</sc></title><p>GLP-1 has shown to improve beta-cell health and suppress glucagon, thereby improving postprandial and fasting hyperglycemia, respectively. As explained above, in concert with the central nervous system, GLP-1 augmentation results in central appetite suppression, weight reduction with secondary benefits on dyslipidemia (reduction in triglyceride, apoB48 and increase in HDL). It has been shown that when fatty acids are applied directly to fetal rat intestinal cell cultures, they stimulate GLP-1 secretion. Incretins are released within 5&#x02013;15 minutes of food ingestion, the time that is insufficient for food to directly stimulate the more distally placed neuroendocrine secreting incretin cells. It is thus believed that there exists a regulatory loop.</p><p>The proposed mechanisms for GLP-1 release are as follows:</p><p>
<list list-type="order"><list-item><p><bold><italic>Proximal&#x02013;distal neuro-enteral regulatory loop</italic></bold>: As explained above, release of GLP-1 from the distal ileum is stimulated in response to nutrients in the proximal gastrointestinal tract. An <italic>indirect</italic> influence of nutrients on the release of GLP-1 is mediated via the autonomic nervous system (vagus, myenteric) wherein afferent signals (vagus nerve) carry impulses to higher centers in the brain (hypothalamus, area postrema, amygdala) in order to modulate feeding, inducing satiety or anorexia (food aversion). The parasympathetic system (vagus) is also hypothesized to carry efferent signals to directly influence the release of GLP-1.[<xref ref-type="bibr" rid="ref74">74</xref>]</p></list-item><list-item><p>Direct stimulatory effect of nutrient related GIP release on GLP-1 release by L-cells.</p></list-item></list>
</p><sec id="sec2-5"><title>Potential benefits</title><p>
<list list-type="order"><list-item><p><bold>Appetite suppression</bold></p></list-item><list-item><p><bold>Delayed gastric emptying causing prandial satiety</bold></p></list-item><list-item><p><bold>Weight reduction/anti-obesity</bold>: This results from the cumulative effect of central appetite suppression, modulation of peripheral taste sensation and gastric slowing (prandial satiety). A meta-analysis has suggested that use of GLP-1 analogues is associated with an average weight loss of approximately 4.76 kg compared to patients receiving insulin therapy. GLP-1 analogues cause reduction in both visceral and subcutaneous (abdominal circumference) adipose tissue. For every 1 cm increase in waist circumference, the relative increase in cardiovascular risk equals approximately 2%. It is well established that intentional weight loss has cardiovascular benefits. Weight loss of approximately less than 20 lb is associated with reduction of diabetes-associated mortality by 32%. Even a modest loss of weight (&#x0003c;10%) significantly improves blood pressure, cholesterol levels and glycemic control.[<xref ref-type="bibr" rid="ref79">79</xref>&#x02013;<xref ref-type="bibr" rid="ref84">84</xref>] GLP-1 analogues are an effective weight management tool that delays the onset of type 2 diabetes. Although not approved for obesity alone, drug therapy that exploits the GLP-axis seems like a potential strategy to counter both obesity and diabetes. With its vast pleiotropic effects, the incretin mimetics threaten to become the mainstay of therapy in patients with diabetes, especially if they are overweight or obese, taking into account the profound metabolic benefits.</p></list-item><list-item><p><bold>Increased insulin secretion (improvement in beta-cell health)</bold>: GLP-1 analogues improve beta-cell health and insulin secretion. Suggested mechanism includes anti-apoptosis with evidence of increased markers of cell proliferation (Ki67).[<xref ref-type="bibr" rid="ref85">85</xref>]</p></list-item><list-item><p><bold>Suppression of glucagon</bold>: The alpha-cells have been found to be dysfunctional (loss of glucose sensing mechanism) in T2DM. The liver too seems to be hypersensitive to the stimulatory effects of glucagon. GLP-1 analogues improve alpha-cell health and their glucose sensing ability. Alpha-cells possess GLP-1Rs, and although direct effects on these receptors have been proposed as mechanisms explaining the glucagon's suppressive effects of GLP-1 analogues, indirect suppressive mechanisms (delayed gastric emptying, improved insulin secretion) cannot be ruled out.[<xref ref-type="bibr" rid="ref86">86</xref>&#x02013;<xref ref-type="bibr" rid="ref90">90</xref>]</p></list-item><list-item><p><bold>Hepatosteatosis</bold>: Hepatic insulin resistance contributes to ectopic fat deposition in the liver, resulting in hepatic steatosis known as non-alcoholic fatty liver disease (NAFLD). NAFLD can later progress to non-alcoholic steatohepatitis (NASH) and cirrhosis. GLP-1 has shown to attenuate weight gain and improve insulin resistance. Weight loss has been shown to reduce hepatic steatosis. It has also been demonstrated that GLP-1Rs are hepatoprotective. They can act directly on the hepatocytes and improve hepatic steatosis. In a meta-analysis of the LEAD program, liraglutide and exanatide have shown to improve NAFLD fibrosis score, biochemical transaminitis/fatty liver independent of weight loss.[<xref ref-type="bibr" rid="ref91">91</xref>&#x02013;<xref ref-type="bibr" rid="ref95">95</xref>]</p></list-item></list>
</p></sec></sec><sec id="sec1-9"><title>I<sc>NSULIN</sc> R<sc>ESISTANCE</sc></title><p>Insulin resistance is associated with an increased risk of metabolic abnormalities (dyslipidemia, T2DM). In one study, waist circumference and body mass index (BMI) were independently associated with CVD risk factors (such as hypertension, metabolic syndrome, and dyslipidemia) in both men and women.[<xref ref-type="bibr" rid="ref96">96</xref>] GLP-1 has shown to reduce insulin sensitivity through restoration of insulin signaling and by reduction of hepatic gluconeogenesis. Enhanced insulin secretion causes increased uptake of glucose in the muscle and adipocyte and reduced outpouring of glucose from the liver.[<xref ref-type="bibr" rid="ref97">97</xref>] Obesity is associated with insulin resistance.</p><p>
<list list-type="simple"><list-item><label>1.</label><p>An adipocyte that is resistant to the actions of insulin releases <italic>free fatty acids</italic> (FFA) into the circulation, which affects glucose uptake in peripheral tissues in several ways.</p><p>
<list list-type="simple"><list-item><label>a.</label><p>FFA directly competes with and inhibits glucose uptake in peripheral tissue (muscle).[<xref ref-type="bibr" rid="ref98">98</xref><xref ref-type="bibr" rid="ref99">99</xref>]</p></list-item><list-item><label>b.</label><p>FFA alters the insulin signaling pathway and down-regulates insulin secretion. It inactivates the intracellular downstream signals involved in the secretion of insulin (phosphoinositide-3-kinase activity).[<xref ref-type="bibr" rid="ref99">99</xref>&#x02013;<xref ref-type="bibr" rid="ref101">101</xref>]</p></list-item></list>
</p></list-item><list-item><label>2)</label><p>Obesity is associated with increased adipocyte apoptosis which in turn results in release of inflammatory cytokines (macrophage chemoattractant protein-1, TNF-alpha, IL-6, and IL-1&#x003b2;) locally (fat cell) and systemically (muscle, liver, etc.). The inflammatory cytokines cause serine phosphorylation of insulin receptor substrate-1 (IRS-1; downstream messenger in insulin secretion), which downgrades the cascade of events leading to insulin secretion and function, contributing to a beta-cell dysfunction.[<xref ref-type="bibr" rid="ref102">102</xref>]</p></list-item></list>
</p><p>GLP analogues cause significant weight loss (reduce FFA), improve insulin secretion and suppress glucagon. In addition, they directly enhance beta-cell fatty acid oxidation[<xref ref-type="bibr" rid="ref103">103</xref>] promoting lipolysis within the beta-cell. This promotes breakdown of triglycerides and causes efflux of FFA from the beta-cell, thereby improving insulin signaling. Taking all the findings, it seems clear that by improving insulin resistance, GLP-1 has clear benefits on cardiovascular system indirectly.</p></sec><sec id="sec1-10"><title>S<sc>KELETAL</sc> E<sc>FFECTS</sc></title><p>A growing body of evidence suggests that by augmenting the incretin system, bone health improves. A study has shown that GLP-1 promotes cellular proliferation and cytoprotection of progenitor bone forming mesenchymal cells. It also prevents these cells from differentiating into adipocytes. NPY has emerged as an important peptide in the regulation of bone remodeling. Central NPY over-expression decreases osteoblastic activity, while on the other hand, specific NYPR1 receptor deletion enhances bone mass. GLP-1 has shown to antagonize the effects of NYP, suggesting that it may help increase bone mass (trabecular and cortical). These effects seem to be dependent mostly on the NPYR1 receptor, with regulatory input from NYPR2 and 4 and the leptin system.[<xref ref-type="bibr" rid="ref104">104</xref>&#x02013;<xref ref-type="bibr" rid="ref107">107</xref>]</p></sec><sec id="sec1-11"><title>W<sc>OUND</sc> H<sc>EALING</sc></title><p>Gliptin (linagliptin) has shown to influence positively macrophage-mediated inflammation response and tissue remodeling, which may have benefits with regard to suppression of vascular inflammation and improvement in wound healing.[<xref ref-type="bibr" rid="ref108">108</xref>]</p></sec><sec id="sec1-12"><title>N<sc>EPHROPROTECTION</sc></title><p>Gliptin (sitagliptin) has shown to reduce albuminuria in a small pilot study, without affecting the glomerular filtration rate, most likely due to its beneficial effect on blood sugar, blood pressure, and inflammation.[<xref ref-type="bibr" rid="ref109">109</xref>]</p></sec><sec sec-type="conclusion" id="sec1-13"><title>C<sc>ONCLUSION</sc></title><p>Augmentation of the incretin axis by use of either GLP-1 agonists or DDP-4 inhibitors represents a novel therapeutic concept that is not only anti-hyperglycemic but has substantial pleiotropic effects. Benefits extend to virtually every organ system, providing cardiovascular stability (anti-ischemic, anti-hypertensive, ionotropic, anti-atherosclerotic) weight loss, neuronal-protection, liver and skeletal health and improvement in insulin resistance. Incretin agonism clearly represents the future of anti-diabetes therapy given its impressive pleitropic actions.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil,</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>R<sc>EFERENCES</sc></title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koro</surname><given-names>CE</given-names></name><name><surname>Bowlin</surname><given-names>SJ</given-names></name><name><surname>Bourgeois</surname><given-names>N</given-names></name><name><surname>Fedder</surname><given-names>DO</given-names></name></person-group><article-title>Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: A preliminary report</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">14693960</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Defronzo</surname><given-names>RA</given-names></name></person-group><article-title>Banting Lecture: From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus</article-title><source>Diabetes</source><year>2009</year><volume>58</volume><fpage>773</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">19336687</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Davidson</surname><given-names>MB</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name><name><surname>Holman</surname><given-names>RR</given-names></name><name><surname>Sherwin</surname><given-names>R</given-names></name><etal/></person-group><article-title>Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>1963</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16873813</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><collab>UK Prospective Diabetes Diabetes Study Group</collab><article-title>UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes</article-title><source>Diabetes Care</source><year>1998</year><volume>21</volume><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">9538975</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charbonnel</surname><given-names>B</given-names></name><name><surname>Cariou</surname><given-names>B</given-names></name></person-group><article-title>Pharmacological management of type 2 diabetes: The potential of incretin-based therapies</article-title><source>Diabetes Obesit Metab</source><year>2011</year><volume>13</volume><fpage>99</fpage><lpage>117</lpage></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayliss</surname><given-names>WM</given-names></name><name><surname>Starling</surname><given-names>EH</given-names></name></person-group><article-title>The mechanism of pancreatic secretion</article-title><source>J Physiol</source><year>1902</year><volume>28</volume><fpage>325</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">16992627</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Barre</surname><given-names>J</given-names></name><name><surname>Still</surname><given-names>EU</given-names></name></person-group><article-title>Studies on the physiology of secretin</article-title><source>Am J Physiol</source><year>1930</year><volume>91</volume><fpage>649</fpage><lpage>53</lpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Barre</surname><given-names>J</given-names></name></person-group><article-title>Sur le possibilit&#x000e9; d&#x02019;un traitement du diab&#x000e8;te par l&#x02019;incr&#x000e9;tine</article-title><source>Bull Acad R Med Belg</source><year>1932</year><volume>12</volume><fpage>620</fpage><lpage>4</lpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>The biology of incretin hormones</article-title><source>Cell Metab</source><year>2006</year><volume>3</volume><fpage>153</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">16517403</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>DJ</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name></person-group><article-title>The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>1696</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">17098089</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meier</surname><given-names>JJ</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name></person-group><article-title>Incretins and the development of type 2 diabetes</article-title><source>Curr Diab Rep</source><year>2006</year><volume>6</volume><fpage>194</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">16898571</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holst</surname></name><name><surname>Jens</surname><given-names>J</given-names></name></person-group><article-title>The physiology and pharmacology of incretins in type 2 diabetes mellitus</article-title><source>Diabet Obesit Metab</source><year>2008</year><volume>10)</volume><issue>Suppl 3</issue><fpage>14</fpage><lpage>21</lpage></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deacon</surname></name><name><surname>Carolyn</surname><given-names>F</given-names></name></person-group><article-title>DPPIV and diabetes</article-title><source>Clin Chem Lab Med</source><year>2008</year><volume>46</volume><fpage>A18</fpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>JH</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Gorrell</surname><given-names>MD</given-names></name><name><surname>Prins</surname><given-names>JB</given-names></name></person-group><article-title>Incretin-based therapies: Review of the physiology, pharmacology and emerging clinical experience</article-title><source>Intern Med J</source><year>2011</year><volume>41</volume><fpage>299</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">21299778</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>HB</given-names></name><name><surname>Branner</surname><given-names>S</given-names></name><name><surname>Wiberg</surname><given-names>FC</given-names></name><name><surname>Wagtmann</surname><given-names>N</given-names></name></person-group><article-title>Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog</article-title><source>Nat Struct Biol</source><year>2003</year><volume>10</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">12483204</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deacon</surname><given-names>CF</given-names></name></person-group><article-title>Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review</article-title><source>Diabet Obesit Metab</source><year>2011</year><volume>13</volume><fpage>7</fpage><lpage>18</lpage></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopsu-Havu</surname><given-names>VK</given-names></name><name><surname>Glenner</surname><given-names>GG</given-names></name></person-group><article-title>A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-[beta]-naphthylamide</article-title><source>Histochemie</source><year>1966</year><volume>7</volume><fpage>197</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">5959122</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinzig</surname><given-names>KP</given-names></name><name><surname>D&#x02019;Alessio</surname><given-names>DA</given-names></name><name><surname>Seeley</surname><given-names>RJ</given-names></name></person-group><article-title>The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness</article-title><source>J Neurosci</source><year>2002</year><volume>22</volume><fpage>10470</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12451146</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>PJ</given-names></name><name><surname>Tang-Christensen</surname><given-names>M</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>&#x000d8;rskov</surname><given-names>C</given-names></name></person-group><article-title>Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem</article-title><source>Neuroscience</source><year>1997</year><volume>77</volume><fpage>257</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9044391</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>NA</given-names></name><name><surname>Mells</surname><given-names>J</given-names></name><name><surname>Dunham</surname><given-names>RM</given-names></name><name><surname>Grakoui</surname><given-names>A</given-names></name><name><surname>Handy</surname><given-names>J</given-names></name><name><surname>Saxena</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis <italic>in vitro</italic> by modulating elements of the insulin signaling pathway</article-title><source>Hepatology</source><year>2010</year><volume>51</volume><fpage>1584</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">20225248</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodbard</surname><given-names>HW</given-names></name><name><surname>Jellinger</surname><given-names>PS</given-names></name><name><surname>Davidson</surname><given-names>JA</given-names></name><name><surname>Einhorn</surname><given-names>D</given-names></name><name><surname>Garber</surname><given-names>AJ</given-names></name><name><surname>Grunberger</surname><given-names>G</given-names></name><etal/></person-group><article-title>Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control</article-title><source>Endocr Pract</source><year>2009</year><volume>15</volume><fpage>540</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">19858063</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Davidson</surname><given-names>MB</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Holman</surname><given-names>RR</given-names></name><name><surname>Sherwin</surname><given-names>R</given-names></name><etal/></person-group><article-title>Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">18945920</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="webpage"><article-title>NICE diabetes treatment algorithm</article-title><date-in-citation>cited in 2010</date-in-citation><comment>Available from:
<uri xlink:type="simple" xlink:href="http://www.nice.org.uk/guidance/CG66">http://www.nice.org.uk/guidance/CG66</uri></comment></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>DJ</given-names></name></person-group><article-title>Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis</article-title><source>Mol Endocrinol</source><year>2003</year><volume>17</volume><fpage>161</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">12554744</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ban</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Cho</surname><given-names>CK</given-names></name><name><surname>Sauv&#x000e9;</surname><given-names>M</given-names></name><name><surname>Diamandis</surname><given-names>EP</given-names></name><name><surname>Backx</surname><given-names>PH</given-names></name><etal/></person-group><article-title>Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor</article-title><source>Endocrinology</source><year>2010</year><volume>151</volume><fpage>1520</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">20172966</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tweedie</surname><given-names>D</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name><name><surname>Holloway</surname><given-names>HW</given-names></name><name><surname>Greig</surname><given-names>NH</given-names></name></person-group><article-title>Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells</article-title><source>J Neurochem</source><year>2010</year><volume>113</volume><fpage>1621</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">20374430</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathanson</surname><given-names>D</given-names></name><name><surname>Zethelius</surname><given-names>B</given-names></name><name><surname>Berne</surname><given-names>C</given-names></name><name><surname>Lind</surname><given-names>L</given-names></name><name><surname>Andr&#x000e9;n</surname><given-names>B</given-names></name><name><surname>Ingelsson</surname><given-names>E</given-names></name><etal/></person-group><article-title>Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men</article-title><source>Diabet Med</source><year>2011</year><volume>28</volume><fpage>301</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">21309838</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ban</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Cho</surname><given-names>CK</given-names></name><name><surname>Sauv&#x000e9;</surname><given-names>M</given-names></name><name><surname>Diamandis</surname><given-names>EP</given-names></name><name><surname>Backx</surname><given-names>PH</given-names></name><etal/></person-group><article-title>Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin (9-39) yet does not require the known GLP-1 receptor</article-title><source>Endocrinology</source><year>2010</year><volume>151</volume><fpage>1520</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">20172966</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gros</surname><given-names>R</given-names></name><name><surname>You</surname><given-names>X</given-names></name><name><surname>Baggio</surname><given-names>LL</given-names></name><name><surname>Kabir</surname><given-names>MG</given-names></name><name><surname>Sadi</surname><given-names>AM</given-names></name><name><surname>Mungrue</surname><given-names>IN</given-names></name><etal/></person-group><article-title>Cardiac function in mice lacking the glucagon-like peptide-1 receptor</article-title><source>Endocrinology</source><year>2003</year><volume>144</volume><fpage>2242</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">12746281</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taegtmeyer</surname><given-names>H</given-names></name></person-group><article-title>Cardiac metabolism as a target for the treatment of heart failure</article-title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>894</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15326079</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randle</surname><given-names>PJ</given-names></name><name><surname>Garland</surname><given-names>PB</given-names></name><name><surname>Hales</surname><given-names>CN</given-names></name><name><surname>Newsholme</surname><given-names>EA</given-names></name></person-group><article-title>The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus</article-title><source>Lancet</source><year>1963</year><volume>1</volume><fpage>785</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">13990765</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>GW</given-names></name><name><surname>Taylor</surname><given-names>CS</given-names></name><name><surname>Taegtmeyer</surname><given-names>H</given-names></name></person-group><article-title>Regulation of energy metabolism of the heart during acute increase in heart work</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>29530</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9792661</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villanueva-Pe&#x000f1;acarrillo</surname><given-names>ML</given-names></name><name><surname>Puente</surname><given-names>J</given-names></name><name><surname>Redondo</surname><given-names>A</given-names></name><name><surname>Clemente</surname><given-names>F</given-names></name><name><surname>Valverde</surname><given-names>I</given-names></name></person-group><article-title>Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models</article-title><source>Endocrine</source><year>2001</year><volume>15</volume><fpage>241</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11720253</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davey</surname><given-names>KA</given-names></name><name><surname>Garlick</surname><given-names>PB</given-names></name><name><surname>Warley</surname><given-names>A</given-names></name><name><surname>Southworth</surname><given-names>R</given-names></name></person-group><article-title>Immunogold labeling study of the distribution of GLUT-1 and GLUT-4 in cardiac tissue following stimulation by insulin or ischemia</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2007</year><volume>292</volume><fpage>H2009</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">17189352</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kavianipour</surname><given-names>M</given-names></name><name><surname>Ehlers</surname><given-names>MR</given-names></name><name><surname>Malmberg</surname><given-names>K</given-names></name><name><surname>Ronquist</surname><given-names>G</given-names></name><name><surname>Ryden</surname><given-names>L</given-names></name><name><surname>Wikstr&#x000f6;m</surname><given-names>G</given-names></name><etal/></person-group><article-title>Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium</article-title><source>Peptides</source><year>2003</year><volume>24</volume><fpage>569</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">12860201</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>AK</given-names></name><name><surname>Mocanu</surname><given-names>MM</given-names></name><name><surname>Carr</surname><given-names>RD</given-names></name><name><surname>Brand</surname><given-names>CL</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name></person-group><article-title>Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>146</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15616022</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Steenbergen</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>E</given-names></name></person-group><article-title>Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C</article-title><source>Circ Res</source><year>2000</year><volume>87</volume><fpage>309</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">10948065</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juhaszova</surname><given-names>M</given-names></name><name><surname>Zorov</surname><given-names>DB</given-names></name><name><surname>Yaniv</surname><given-names>Y</given-names></name><name><surname>Nuss</surname><given-names>HB</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Sollott</surname><given-names>SJ</given-names></name></person-group><article-title>Role of glycogen synthase kinase-3beta in cardio-protection</article-title><source>Circ Res</source><year>2009</year><volume>104</volume><fpage>1240</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">19498210</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Pachori</surname><given-names>AS</given-names></name><name><surname>Ward</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Heme oxygenase-1 (HO-1) inhibits post myocardial infarct remodeling and restores ventricular function</article-title><source>FASEB J</source><year>2006</year><volume>20</volume><fpage>207</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">16449792</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolaidis</surname><given-names>LA</given-names></name><name><surname>Mankad</surname><given-names>S</given-names></name><name><surname>Sokos</surname><given-names>GG</given-names></name><name><surname>Miske</surname><given-names>G</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Elahi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>962</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">14981009</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokos</surname><given-names>GG</given-names></name><name><surname>Nikolaidis</surname><given-names>LA</given-names></name><name><surname>Mankad</surname><given-names>S</given-names></name><name><surname>Elahi</surname><given-names>D</given-names></name><name><surname>Shannon</surname><given-names>RP</given-names></name></person-group><article-title>Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure</article-title><source>J Card Fail</source><year>2006</year><volume>12</volume><fpage>694</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17174230</pub-id></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marney</surname><given-names>A</given-names></name><name><surname>Kunchakarra</surname><given-names>S</given-names></name><name><surname>Byrne</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>NJ</given-names></name></person-group><article-title>Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans</article-title><source>Hypertension</source><year>2010</year><volume>56</volume><fpage>728</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">20679179</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Nangaku</surname><given-names>M</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name></person-group><article-title>The role of incretins in salt-sensitive hypertension: The potential use of dipeptidyl peptidase-IV inhibitors</article-title><source>Curr Opin Nephrol Hypertens</source><year>2011</year><volume>20</volume><fpage>476</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">21738030</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Moreno</surname><given-names>C</given-names></name><name><surname>Hoagland</surname><given-names>KM</given-names></name><name><surname>Dahly</surname><given-names>A</given-names></name><name><surname>Ditter</surname><given-names>K</given-names></name><name><surname>Mistry</surname><given-names>M</given-names></name><etal/></person-group><article-title>Anti-hypertensive effect of glucagons-like peptide 1 in Dahl salt-sensitive rats</article-title><source>J Hypertens</source><year>2003</year><volume>21</volume><fpage>1125</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">12777949</pub-id></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobrian</surname><given-names>AD</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Lindsay</surname><given-names>JW</given-names></name><name><surname>Leone</surname><given-names>KA</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Coben</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice</article-title><source>Am J Physiol Endocrinol Metab</source><year>2011</year><volume>300</volume><fpage>E410</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">21081706</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>K</given-names></name><name><surname>Kume</surname><given-names>S</given-names></name><name><surname>Araki</surname><given-names>S</given-names></name><name><surname>Sakaguchi</surname><given-names>M</given-names></name><name><surname>Chin-Kanasaki</surname><given-names>M</given-names></name><name><surname>Isshiki</surname><given-names>K</given-names></name><etal/></person-group><article-title>Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model</article-title><source>Biochem Biophys Res Commun</source><year>2009</year><volume>380</volume><fpage>44</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19150338</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>C</given-names></name><name><surname>Mistry</surname><given-names>M</given-names></name><name><surname>Roman</surname><given-names>RJ</given-names></name></person-group><article-title>Renal effects of glucagon-like peptide in rats</article-title><source>Eur J Pharmacol</source><year>2002</year><volume>434</volume><fpage>163</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11779579</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>A</given-names></name><name><surname>Hoogwerf</surname><given-names>BJ</given-names></name><name><surname>Burger</surname><given-names>J</given-names></name><name><surname>Bruce</surname><given-names>S</given-names></name><name><surname>Macconell</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind, placebo-controlled, randomized pilot study</article-title><source>Cardiovasc Diabetol</source><year>2010</year><volume>9</volume><fpage>6</fpage><pub-id pub-id-type="pmid">20109208</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okerson</surname><given-names>T</given-names></name><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Stonehouse</surname><given-names>A</given-names></name><name><surname>Brodows</surname><given-names>R</given-names></name></person-group><article-title>Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes</article-title><source>Am J Hypertens</source><year>2010</year><volume>23</volume><fpage>334</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20019672</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arakawa</surname><given-names>M</given-names></name><name><surname>Mita</surname><given-names>T</given-names></name><name><surname>Azuma</surname><given-names>K</given-names></name><name><surname>Ebato</surname><given-names>C</given-names></name><name><surname>Goto</surname><given-names>H</given-names></name><name><surname>Nomiyama</surname><given-names>T</given-names></name><etal/></person-group><article-title>Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4</article-title><source>Diabetes</source><year>2010</year><volume>59</volume><fpage>1030</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">20068138</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Dear</surname><given-names>AE</given-names></name><name><surname>Knudsen</surname><given-names>LB</given-names></name><name><surname>Simpson</surname><given-names>RW</given-names></name></person-group><article-title>A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules</article-title><source>J Endocrinol</source><year>2009</year><volume>201</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">19136619</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nystr&#x000f6;m</surname><given-names>T</given-names></name><name><surname>Gutniak</surname><given-names>MK</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Ahr&#x000e9;n</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease</article-title><source>Am J Physiol Endocrinol Metab</source><year>2004</year><volume>287</volume><fpage>E1209</fpage><lpage>E1215</lpage><pub-id pub-id-type="pmid">15353407</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nystr&#x000f6;m</surname><given-names>T</given-names></name><name><surname>Gutniak</surname><given-names>MK</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Ahr&#x000e9;n</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease</article-title><source>Am J Physiol Endocrinol Metab</source><year>2004</year><volume>287</volume><fpage>E1209</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">15353407</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobrian</surname><given-names>AD</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Lindsay</surname><given-names>JW</given-names></name><name><surname>Leone</surname><given-names>KA</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Coben</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice</article-title><source>Am J Physiol Endocrinol Metab</source><year>2011</year><volume>300</volume><fpage>E410</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">21081706</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobrian</surname><given-names>AD</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Lindsay</surname><given-names>JW</given-names></name><name><surname>Leone</surname><given-names>KA</given-names></name><name><surname>Ma</surname><given-names>K</given-names></name><name><surname>Coben</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice</article-title><source>Am J Physiol Endocrinol Metab</source><year>2011</year><volume>300</volume><fpage>E410</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">21081706</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname><given-names>ES</given-names></name><name><surname>Silberman</surname><given-names>C</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name><name><surname>Berria</surname><given-names>R</given-names></name></person-group><article-title>Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>1759</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">20460445</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunck</surname><given-names>MC</given-names></name><name><surname>Corn&#x000e9;r</surname><given-names>A</given-names></name><name><surname>Eliasson</surname><given-names>B</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name><name><surname>Shaginian</surname><given-names>RM</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>One-year treatment with exenatide vs.insulin glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress</article-title><source>Atherosclerosis</source><year>2010</year><volume>212</volume><fpage>223</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20494360</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahr&#x000e9;n</surname><given-names>B</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name></person-group><article-title>The islet enhancer vildagliptin: Mechanisms of improved glucose metabolism</article-title><source>Int J Clin Pract Suppl</source><year>2008</year><volume>159</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">18269436</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>DF</given-names></name><name><surname>Thompson</surname><given-names>TJ</given-names></name><name><surname>Thun</surname><given-names>M</given-names></name><name><surname>Flanders</surname><given-names>D</given-names></name><name><surname>Pamuk</surname><given-names>E</given-names></name><name><surname>Byers</surname><given-names>T</given-names></name></person-group><article-title>Intentional weight loss and mortality among overweight individuals with diabetes</article-title><source>Diabetes Care</source><year>2000</year><volume>23</volume><fpage>1499</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">11023143</pub-id></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>DJ</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name><etal/></person-group><article-title>and DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>1240</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">18782641</pub-id></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charbonnel</surname><given-names>B</given-names></name><name><surname>Cariou</surname><given-names>B</given-names></name></person-group><article-title>Pharmacological management of type 2 diabetes: The potential of incretin-based therapies</article-title><source>Diabet Obes Metab</source><year>2011</year><volume>13</volume><fpage>99</fpage><lpage>117</lpage></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFronzo</surname><given-names>RA</given-names></name><name><surname>Ratner</surname><given-names>RE</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>DD</given-names></name><name><surname>Fineman</surname><given-names>MS</given-names></name><name><surname>Baron</surname><given-names>AD</given-names></name></person-group><article-title>Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>1092</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">15855572</pub-id></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Henry</surname><given-names>RR</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>DD</given-names></name><name><surname>Fineman</surname><given-names>MS</given-names></name><name><surname>Baron</surname><given-names>AD</given-names></name></person-group><collab>Exenatide-113 Clinical Study Group</collab><article-title>Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>2628</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">15504997</pub-id></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kendall</surname><given-names>DM</given-names></name><name><surname>Riddle</surname><given-names>MC</given-names></name><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Zhuang</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>DD</given-names></name><name><surname>Fineman</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>1083</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">15855571</pub-id></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luchsinger</surname><given-names>JA</given-names></name><name><surname>Tang</surname><given-names>MX</given-names></name><name><surname>Shea</surname><given-names>S</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name></person-group><article-title>Hyperinsulinemia and risk of Alzheimer disease</article-title><source>Neurology</source><year>2004</year><volume>63</volume><fpage>1187</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15477536</pub-id></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akter</surname><given-names>K</given-names></name><name><surname>Lanza</surname><given-names>EA</given-names></name><name><surname>Martin</surname><given-names>SA</given-names></name><name><surname>Myronyuk</surname><given-names>N</given-names></name><name><surname>Rua</surname><given-names>M</given-names></name><name><surname>Raffa</surname><given-names>RB</given-names></name></person-group><article-title>Diabetes mellitus and Alzheimer's disease: Shared pathology and treatment?</article-title><source>Br J Clin Pharmacol</source><year>2011</year><volume>71</volume><fpage>365</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">21284695</pub-id></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ristow</surname><given-names>M</given-names></name></person-group><article-title>Neurodegenerative disorders associated with diabetes mellitus</article-title><source>J Mol Med</source><year>2004</year><volume>82</volume><fpage>510</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">15175861</pub-id></element-citation></ref><ref id="ref68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoyer</surname><given-names>S</given-names></name></person-group><article-title>Glucose metabolism and insulin receptor signal transduction in Alzheimer disease</article-title><source>Eur J Pharmacol</source><year>2004</year><volume>490</volume><fpage>115</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">15094078</pub-id></element-citation></ref><ref id="ref69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname><given-names>JM</given-names></name><name><surname>Margolskee</surname><given-names>RF</given-names></name></person-group><article-title>Taste cells of the gut and gastrointestinal chemosensation</article-title><source>Mol Interv</source><year>2008</year><volume>8</volume><fpage>78</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">18403652</pub-id></element-citation></ref><ref id="ref70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larhammar</surname><given-names>D</given-names></name></person-group><article-title>Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide</article-title><source>Regul Pept</source><year>1996</year><volume>65</volume><fpage>165</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">8897639</pub-id></element-citation></ref><ref id="ref71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>TM</given-names></name><name><surname>Breininger</surname><given-names>JF</given-names></name><name><surname>Baskin</surname><given-names>DG</given-names></name><name><surname>Schwartz</surname><given-names>MW</given-names></name></person-group><article-title>Coexpression of AgRP and NPY in fasting-activated hypothalamic neurons</article-title><source>Nat Neurosci</source><year>1998</year><volume>1</volume><fpage>271</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">10195157</pub-id></element-citation></ref><ref id="ref72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inui</surname><given-names>A</given-names></name></person-group><article-title>Neuropeptide Y feeding receptors: Are multiple subtypes involved?</article-title><source>Trends Pharmacol Sci</source><year>1999</year><volume>20</volume><fpage>43</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10101961</pub-id></element-citation></ref><ref id="ref73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuse</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>R</given-names></name><name><surname>Sugahara</surname><given-names>K</given-names></name><name><surname>Kano</surname><given-names>K</given-names></name><name><surname>Hasegawa</surname><given-names>S</given-names></name></person-group><article-title>Influence of fasting and neuropeptide Y on the suppressive food intake induced by intracerebroventricular injection of glucagon-like peptide-1 in the neonatal chick</article-title><source>Brain Res</source><year>1997</year><volume>764</volume><fpage>289</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">9295227</pub-id></element-citation></ref><ref id="ref74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>GW</given-names></name><name><surname>Lin</surname><given-names>JE</given-names></name><name><surname>Valentino</surname><given-names>MA</given-names></name><name><surname>Colon-Gonzalez</surname><given-names>F</given-names></name><name><surname>Waldman</surname><given-names>SA</given-names></name></person-group><article-title>Regulation of appetite to treat obesity</article-title><source>Exp Rev Clin Pharmacol</source><year>2011</year><volume>4</volume><fpage>243</fpage><lpage>59</lpage></element-citation></ref><ref id="ref75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turton</surname><given-names>MD</given-names></name><name><surname>O&#x02019;Shea</surname><given-names>D</given-names></name><name><surname>Gunn</surname><given-names>I</given-names></name><name><surname>Beck</surname><given-names>SA</given-names></name><name><surname>Edwards</surname><given-names>CM</given-names></name><name><surname>Meeran</surname><given-names>K</given-names></name><etal/></person-group><article-title>A role for glucagon-like peptide-1 in the central regulation of feeding</article-title><source>Nature</source><year>1996</year><volume>379</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">8538742</pub-id></element-citation></ref><ref id="ref76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tauchi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>D&#x02019;Alessio</surname><given-names>DA</given-names></name><name><surname>Stern</surname><given-names>JE</given-names></name><name><surname>Herman</surname><given-names>JP</given-names></name></person-group><article-title>Distribution of glucagon-like peptide-1 immunoreactivity in the hypothalamic paraventricular and supraoptic nuclei</article-title><source>J Chem Neuroanat</source><year>2008</year><volume>36</volume><fpage>144</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18773953</pub-id></element-citation></ref><ref id="ref77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layer</surname><given-names>P</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>GLP-1: A humoral mediator of the ileal brake in humans?</article-title><source>Digestion</source><year>1993</year><volume>54</volume><fpage>385</fpage><lpage>6</lpage></element-citation></ref><ref id="ref78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>JM</given-names></name><name><surname>Halaas</surname><given-names>JL</given-names></name></person-group><article-title>Leptin and the regulation of body weight in mammals</article-title><source>Nature</source><year>1998</year><volume>395</volume><fpage>763</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9796811</pub-id></element-citation></ref><ref id="ref79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>MW</given-names></name><name><surname>Seeley</surname><given-names>RJ</given-names></name><name><surname>Campfield</surname><given-names>LA</given-names></name><name><surname>Burn</surname><given-names>P</given-names></name><name><surname>Baskin</surname><given-names>DG</given-names></name></person-group><article-title>Identification of targets of leptin action in rat hypothalamus</article-title><source>J Clin Invest</source><year>1996</year><volume>98</volume><fpage>1101</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8787671</pub-id></element-citation></ref><ref id="ref80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freemantle</surname><given-names>N</given-names></name><name><surname>Holmes</surname><given-names>J</given-names></name><name><surname>Hockey</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>How strong is the association between abdominal obesity and the incidence of type 2 diabetes?</article-title><source>Int J Clin Pract</source><year>2008</year><volume>62</volume><fpage>1391</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18557792</pub-id></element-citation></ref><ref id="ref81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jendle</surname><given-names>J</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Frid</surname><given-names>A</given-names></name><name><surname>Hermansen</surname><given-names>K</given-names></name><name><surname>D&#x000fc;ring</surname><given-names>M</given-names></name><etal/></person-group><article-title>Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue</article-title><source>Diabet Obes Metab</source><year>2009</year><volume>11</volume><fpage>1163</fpage><lpage>72</lpage></element-citation></ref><ref id="ref82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amori</surname><given-names>RE</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name><name><surname>Pittas</surname><given-names>AG</given-names></name></person-group><article-title>Efficacy and safety of incretin therapy in Type 2 diabetes: Systematic review and meta-analysis</article-title><source>J Am Med Assoc</source><year>2007</year><volume>298</volume><fpage>194</fpage><lpage>206</lpage></element-citation></ref><ref id="ref83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Koning</surname><given-names>L</given-names></name><name><surname>Merchant</surname><given-names>AT</given-names></name><name><surname>Pogue</surname><given-names>J</given-names></name><name><surname>Anand</surname><given-names>SS</given-names></name></person-group><article-title>Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: Meta-regression analysis of prospective studies</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><fpage>850</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17403720</pub-id></element-citation></ref><ref id="ref84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>DF</given-names></name><name><surname>Pamuk</surname><given-names>E</given-names></name><name><surname>Thun</surname><given-names>M</given-names></name><name><surname>Flanders</surname><given-names>D</given-names></name><name><surname>Byers</surname><given-names>T</given-names></name><name><surname>Heath</surname><given-names>C</given-names></name></person-group><article-title>Prospective study of intentional weight loss and mortality in overweight white men aged 40-64 years</article-title><source>Am J Epidemiol</source><year>1999</year><volume>149</volume><fpage>491</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">10084238</pub-id></element-citation></ref><ref id="ref85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>DJ</given-names></name></person-group><article-title>Beneficial health effects of modest weight loss</article-title><source>Int J Obes</source><year>1992</year><volume>16</volume><fpage>397</fpage><lpage>415</lpage></element-citation></ref><ref id="ref86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toso</surname><given-names>C</given-names></name><name><surname>McCall</surname><given-names>M</given-names></name><name><surname>Emamaullee</surname><given-names>J</given-names></name><name><surname>Merani</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>J</given-names></name><name><surname>Edgar</surname><given-names>R</given-names></name><etal/></person-group><article-title>Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture</article-title><source>Transplant Int</source><year>2010</year><volume>23</volume><fpage>259</fpage><lpage>65</lpage></element-citation></ref><ref id="ref87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunning</surname><given-names>BE</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Ahr&#x000e9;n</surname><given-names>B</given-names></name></person-group><article-title>Alpha cell function in health and disease: Influence of glucagon-like peptide-1</article-title><source>Diabetologia</source><year>2005</year><volume>48</volume><fpage>1700</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">16132964</pub-id></element-citation></ref><ref id="ref88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>AD</given-names></name><name><surname>Schaeffer</surname><given-names>L</given-names></name><name><surname>Shragg</surname><given-names>P</given-names></name><name><surname>Kolterman</surname><given-names>OG</given-names></name></person-group><article-title>Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics</article-title><source>Diabetes</source><year>1987</year><volume>36</volume><fpage>274</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">2879757</pub-id></element-citation></ref><ref id="ref89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hare</surname><given-names>KJ</given-names></name><name><surname>Vilsb&#x000f8;ll</surname><given-names>T</given-names></name><name><surname>Asmar</surname><given-names>M</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Knop</surname><given-names>FK</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name></person-group><article-title>The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action</article-title><source>Diabetes</source><year>2010</year><volume>59</volume><fpage>1765</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">20150286</pub-id></element-citation></ref><ref id="ref90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Dijk</surname><given-names>G</given-names></name><name><surname>Lindskog</surname><given-names>S</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Steffens</surname><given-names>AB</given-names></name><name><surname>Ahr&#x000e9;n</surname><given-names>B</given-names></name></person-group><article-title>Effects of glucagon-like peptide-I on glucose turnover in rats</article-title><source>Am J Physiol</source><year>1996</year><volume>270</volume><fpage>E1015</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">8764187</pub-id></element-citation></ref><ref id="ref91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willms</surname><given-names>B</given-names></name><name><surname>Werner</surname><given-names>J</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Orskov</surname><given-names>C</given-names></name><name><surname>Creutzfeldt</surname><given-names>W</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name></person-group><article-title>Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients</article-title><source>J Clin Endocrinol Metab</source><year>1996</year><volume>81</volume><fpage>327</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">8550773</pub-id></element-citation></ref><ref id="ref92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomas</surname><given-names>E</given-names></name><name><surname>Wood</surname><given-names>JA</given-names></name><name><surname>Stanojevic</surname><given-names>V</given-names></name><name><surname>Habener</surname><given-names>JF</given-names></name></person-group><article-title>Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice</article-title><source>Diabet Obes Metab</source><year>2011</year><volume>13</volume><fpage>26</fpage><lpage>33</lpage></element-citation></ref><ref id="ref93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomas</surname><given-names>E</given-names></name><name><surname>Wood</surname><given-names>JA</given-names></name><name><surname>Stanojevic</surname><given-names>V</given-names></name><name><surname>Habener</surname><given-names>JF</given-names></name></person-group><article-title>Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice</article-title><source>Diabet Obes Metab</source><year>2011</year><volume>13</volume><fpage>26</fpage><lpage>33</lpage></element-citation></ref><ref id="ref94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>NA</given-names></name><name><surname>Mells</surname><given-names>J</given-names></name><name><surname>Dunham</surname><given-names>RM</given-names></name><name><surname>Grakoui</surname><given-names>A</given-names></name><name><surname>Handy</surname><given-names>J</given-names></name><name><surname>Saxena</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis <italic>in vitro</italic> by modulating elements of the insulin signaling pathway</article-title><source>Hepatology</source><year>2010</year><volume>51</volume><fpage>1584</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">20225248</pub-id></element-citation></ref><ref id="ref95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>MJ</given-names></name><name><surname>Falahati</surname><given-names>A</given-names></name><name><surname>Braun</surname><given-names>OO</given-names></name><name><surname>Schmidt</surname><given-names>WE</given-names></name><name><surname>Gough</surname><given-names>S</given-names></name><name><surname>Newsome</surname><given-names>PN</given-names></name></person-group><article-title>High prevalence of advanced NAFLD in Type 2 diabetic patients with normal liver enzymes and effect of liraglutide on NAFLD: Meta-analysis of the LEAD program</article-title><source>Diabetologia</source><year>2010</year><volume>53</volume><fpage>1552</fpage><pub-id pub-id-type="pmid">20407743</pub-id></element-citation></ref><ref id="ref96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulchandani</surname><given-names>D</given-names></name><name><surname>Nachnani</surname><given-names>JS</given-names></name><name><surname>Eaton</surname><given-names>C</given-names></name><name><surname>Hamburg</surname><given-names>M</given-names></name></person-group><article-title>Association of exenatide with liver enzymes in patients with type 2 diabetes</article-title><source>Endocrinologist</source><year>2009</year><volume>19</volume><fpage>114</fpage><lpage>5</lpage></element-citation></ref><ref id="ref97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><etal/></person-group><article-title>Body fat distribution and their associations with cardiovascular risk, insulin resistance and [beta]-cell function: Are there differences between men and women?</article-title><source>Int J Clin Pract</source><year>2011</year><volume>65</volume><fpage>592</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">21489083</pub-id></element-citation></ref><ref id="ref98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Shigihara</surname><given-names>T</given-names></name><name><surname>Hahm</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>MJ</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><etal/></person-group><article-title>Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><fpage>1671</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17369525</pub-id></element-citation></ref><ref id="ref99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martyn</surname><given-names>JA</given-names></name><name><surname>Kaneki</surname><given-names>M</given-names></name><name><surname>Yasuhara</surname><given-names>S</given-names></name></person-group><article-title>Obesity-induced Insulin resistance and hyperglycemia: Etiologic factors and molecular mechanisms</article-title><source>Anesthesiology</source><year>2008</year><volume>109</volume><fpage>137</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">18580184</pub-id></element-citation></ref><ref id="ref100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boden</surname><given-names>G</given-names></name></person-group><article-title>Role of fatty acids in the pathogenesis of insulin resistance and NIDDM</article-title><source>Diabetes</source><year>1997</year><volume>46</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">8971073</pub-id></element-citation></ref><ref id="ref101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dresner</surname><given-names>A</given-names></name><name><surname>Laurent</surname><given-names>D</given-names></name><name><surname>Marcucci</surname><given-names>M</given-names></name><name><surname>Griffin</surname><given-names>ME</given-names></name><name><surname>Dufour</surname><given-names>S</given-names></name><name><surname>Cline</surname><given-names>GW</given-names></name><etal/></person-group><article-title>Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity</article-title><source>J Clin Invest</source><year>1999</year><volume>103</volume><fpage>253</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9916137</pub-id></element-citation></ref><ref id="ref102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinti</surname><given-names>S</given-names></name><name><surname>Mitchell</surname><given-names>G</given-names></name><name><surname>Barbatelli</surname><given-names>G</given-names></name><name><surname>Murano</surname><given-names>I</given-names></name><name><surname>Ceresi</surname><given-names>E</given-names></name><name><surname>Faloia</surname><given-names>E</given-names></name><etal/></person-group><article-title>Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans</article-title><source>J Lipid Res</source><year>2005</year><volume>46</volume><fpage>2347</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">16150820</pub-id></element-citation></ref><ref id="ref103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emanuelli</surname><given-names>B</given-names></name><name><surname>Peraldi</surname><given-names>P</given-names></name><name><surname>Filloux</surname><given-names>C</given-names></name><name><surname>Chavey</surname><given-names>C</given-names></name><name><surname>Freidinger</surname><given-names>K</given-names></name><name><surname>Hilton</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-[alpha] in the adipose tissue of obese mice</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>47944</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11604392</pub-id></element-citation></ref><ref id="ref104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaney</surname><given-names>GC</given-names></name><name><surname>Civelek</surname><given-names>VN</given-names></name><name><surname>Richard</surname><given-names>AM</given-names></name><name><surname>Dillon</surname><given-names>JS</given-names></name><name><surname>Deeney</surname><given-names>JT</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Glucagon-like peptide 1 stimulates lipolysis in clonal pancreatic [beta]-cells (HIT)</article-title><source>Diabetes</source><year>2001</year><volume>50</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">11147795</pub-id></element-citation></ref><ref id="ref105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanz</surname><given-names>C</given-names></name><name><surname>V&#x000e1;zquez</surname><given-names>P</given-names></name><name><surname>Bl&#x000e1;zquez</surname><given-names>C</given-names></name><name><surname>Barrio</surname><given-names>PA</given-names></name><name><surname>Alvarez Mdel</surname><given-names>M</given-names></name><name><surname>Bl&#x000e1;zquez</surname><given-names>E</given-names></name></person-group><article-title>Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow</article-title><source>Am J Physiol Endocrinol Metab</source><year>2010</year><volume>298</volume><fpage>E634</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">20040695</pub-id></element-citation></ref><ref id="ref106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>NJ</given-names></name><name><surname>Nguyen</surname><given-names>AD</given-names></name><name><surname>Enriquez</surname><given-names>RF</given-names></name><name><surname>Doyle</surname><given-names>KL</given-names></name><name><surname>Sainsbury</surname><given-names>A</given-names></name><name><surname>Baldock</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Osteoblast specific Y1 receptor deletion enhances bone mass</article-title><source>Bone</source><year>2011</year><volume>48</volume><fpage>461</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21040809</pub-id></element-citation></ref><ref id="ref107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldock</surname><given-names>PA</given-names></name><name><surname>Lee</surname><given-names>NJ</given-names></name><name><surname>Driessler</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Allison</surname><given-names>S</given-names></name><name><surname>Stehrer</surname><given-names>B</given-names></name></person-group><article-title>Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e8415</fpage><pub-id pub-id-type="pmid">20027231</pub-id></element-citation></ref><ref id="ref108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ta</surname><given-names>NN</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Schuyler</surname><given-names>CA</given-names></name><name><surname>Lopes-Virella</surname><given-names>MF</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes</article-title><source>Atherosclerosis</source><year>2010</year><volume>213</volume><fpage>429</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">20843518</pub-id></element-citation></ref><ref id="ref109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>S</given-names></name></person-group><article-title>Sitagliptin reduces albuminuria in patients with type 2 diabetes</article-title><source>Endocr J</source><year>2011</year><volume>58</volume><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">21206136</pub-id></element-citation></ref></ref-list></back></article>